Pharmaceutical

AN2 slashes staff by 50% after lead antibiotic flunks in Phase II/III trial

The company stock was down by over 22.7% in premarket trading as AN2 shared trial termination plans for epetraborole.

Aug 11, 2024 - 04:00
AN2 slashes staff by 50% after lead antibiotic flunks in Phase II/III trial
The company stock was down by over 22.7% in premarket trading as AN2 shared trial termination plans for epetraborole.
Read the original article

Tags:

Previous Article

Eli Lilly boosts sales forecast by $3bn as diabetes and weight loss drugs propel...

Next Article

Adaptimmune leads in soft tissue sarcoma therapy with first TCR approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Why it won’t be so easy for medicine to displace BMI

Why it won’t be so easy for medicine to displace BMI

Jun 16, 2023

STAT+: At JPM, Bristol’s new CEO appeals to history to try to soothe investors’ nerves

STAT+: At JPM, Bristol’s new CEO appeals to history to ...

Jan 8, 2024

STAT+: Pharma loses a key battle over a state law concerning 340B pharmacies

STAT+: Pharma loses a key battle over a state law conce...

Mar 13, 2024